Thank you Quynh Vu for your excellent overview of the STOPAH trial (Prednisolone or Pentoxifylline for Alcoholic Hepatitis)

Conclusions of the study:

  • Pentoxifylline did not improve survival in patients with alcoholic hepatitis
  • Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or 1 year

Main points: STOPAH PowerPoint

Read Full Article: STOPAH Trial